Richard Lyttle

President & CEO, Radius Health

Professional Overview

Richard Lyttle is the President and Chief Executive Officer of Radius Health, a leading biopharmaceutical company focused on developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology, and endocrinology. With a strong background in the life sciences industry, Lyttle leverages his extensive expertise in strategic leadership, operational excellence, and scientific innovation to drive Radius Health's growth and impact.

Experience Summary

Current Role

As President and CEO, Lyttle is responsible for setting the strategic vision and direction for Radius Health, as well as overseeing all aspects of the company's operations. Under his leadership, Radius Health has made significant strides in advancing its pipeline of novel therapeutics, enhancing its commercial capabilities, and strengthening its position as a leading innovator in the biopharmaceutical industry.

Career Progression

Prior to joining Radius Health, Lyttle held senior executive roles at several prominent biopharmaceutical companies, including serving as the Chief Operating Officer at Ironwood Pharmaceuticals and the Vice President of Global Marketing at Genzyme Corporation. His diverse professional experience has equipped him with a deep understanding of the complex challenges and opportunities facing the industry, enabling him to drive strategic decision-making and operational excellence at Radius Health.

Academic Background

Lyttle holds a Bachelor of Science degree in Biochemistry from the University of Massachusetts, Amherst, where he graduated with honors. He has also completed executive education programs at leading business schools, further enhancing his strategic and leadership capabilities.

Areas of Expertise

• Biopharmaceutical industry expertise, with a focus on osteoporosis, oncology, and endocrinology

• Strategic leadership and vision setting

• Operational excellence and scalable business model development

• Innovative product development and commercialization

• Collaborative partnership and alliance management

• Effective communication and stakeholder engagement

Professional Impact

Under Lyttle's leadership, Radius Health has achieved significant milestones, including the successful launch and commercial expansion of its flagship product, the first-in-class osteoporosis treatment TYMLOS®. Additionally, the company has made substantial progress in advancing its pipeline of novel therapeutics, positioning Radius Health as a key player in the biopharmaceutical industry.

Conclusion

With his proven track record of success, deep industry expertise, and visionary leadership, Richard Lyttle is well-positioned to drive Radius Health's continued growth and innovation, ultimately delivering value to patients, shareholders, and the broader healthcare ecosystem.